Atera’s CEO Dr Bart De Wever will take part in a Roundtable on : Latest advancements of in vitro evaluation of cosmetics – from regulatory compliance of ingredients to finish products claims on the occasion of the In-Cosmetics conference in Barcelona this coming 16th of April in Barcelona Spain.
“The use of human skin models in pharmacology and toxicology has become a widely accepted approach for the evaluation of dermato-cosmetic products, both finished formulations and active ingredients.”
Today, engineered three-dimensional tissue models from human cells of the skin, cornea, mucosa, and respiratory tract are widely used in pharmaceutical, chemical, consumer, and cosmetic industries as alternatives to animal testing. The currently available scientifically valid 3D tissue-engineered models, however, are protected by patents and/or are being commercialized using proprietary tissue culture procedures owned by only a few private companies.
February 17, 2015, Atera’s CEO Dr Bart De Wever will talk on the subject of “The Relevance of Tissue Engineering from a European policy perspective” on the occasion of the 5-year final meeting of the EU project VascuBone.